Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [3584]

ASH 2021: Immune-boosting antibody treatment isatuximab meets primary endpoint for multiple myeloma

ASH 2021: Immune-boosting antibody treatment isatuximab meets primary endpoint for multiple myeloma

ASH 2021: ZUMA-7 demonstrates lasting benefits of CAR-T therapy over current standard of care for large B-cell lymphoma

ASH 2021: ZUMA-7 demonstrates lasting benefits of CAR-T therapy over current standard of care for large B-cell...

SABCS 2021: Subgroup analysis of trastuzumab deruxtecan shows ‘encouraging’ results in controlling stable brain metastases in HER2-positive metastatic breast cancer

SABCS 2021: Subgroup analysis of trastuzumab deruxtecan shows ‘encouraging’ results in controlling stable brain...

Moderate immune response is more effective against leukaemia

Moderate immune response is more effective against leukaemia

In breast cancer, the best defence is a strong offence

In breast cancer, the best defence is a strong offence

Chemoimmunotherapy dramatically improved survival of high-risk neuroblastoma patients

Chemoimmunotherapy dramatically improved survival of high-risk neuroblastoma patients

Which glioblastoma patients will respond to immunotherapy?

Which glioblastoma patients will respond to immunotherapy?

Researchers find how immune cells in the tumour microenvironment make things worse

Researchers find how immune cells in the tumour microenvironment make things worse

Antihistamines can influence immunotherapy response by enhancing T cell activation

Antihistamines can influence immunotherapy response by enhancing T cell activation

GABA released by B-cells blunts the immune response to tumours

GABA released by B-cells blunts the immune response to tumours

More from ecancer